Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Journal of Medicinal Chemistry

Volumn 49, Issue 9, 2006, Pages 2845-2849

  Biot, Christophe ^a   Daher, Wassim ^b   Chavain, Natascha ^a   Fandeur, Thierry ^c   Khalife, Jamal ^b   Dive, Daniel ^b   De Clercq, Erik ^d  

^a UNITÉ DE CATALYSE ET DE CHIMIE DU SOLIDE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c CEMAGREF   (France)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [2 [[(7 CHLORO 4 QUINOLYL)AMINO]METHYL]FERROCENYLMETHYL](ETHYL)AMINO] 1 ETHANOL; [2 [2 [[(7 CHLORO 4 QUINOLYL)AMINO]METHYL]FERROCENYLMETHYL](METHYL)AMINO] 1 ETHANOL; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ARTESUNATE; CHLOROQUINE; FERROQUINE DERIVATIVE; HYDROXYCHLOROQUINE; HYDROXYFERROQUINE DERIVATIVE; MEFLOQUINE; ORGANOMETALLIC COMPOUND; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ASIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENDEMIC DISEASE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

ANIMALS; ANTIMALARIALS; ANTIVIRAL AGENTS; DRUG DESIGN; FERROUS COMPOUNDS; HIV-1; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; QUINOLINES; SARS VIRUS;

EID: 33646449766     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601856     Document Type: Article

References (34)

1. Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434, 214-217.
2. World Health Organization: Chemotherapy of Malaria and Resistance in Plasmodium falciparum: What next? Trends Parasitol. 2001, 17, 582-588.
3. Hastings, I. M. The origins of antimalarial drug resistance. Trends Parasitol. 2004, 512-518.
4. Biot, C.; Chibale, K. Novel Approaches to Antimalarial Drug Discovery Curr. Drug Targets - Infectious Disorders 2006, in press.
5. Tripathi, R. P., Mishra, R. C., Dwivedi, N., Tewari, N., Verma, S. S. Current Status of Malaria Control. Curr. Med. Chem. 2005, 12, 2643-2659.
6. Biagini, G. A.; O'Neill, P. M.; Bray, P. G.; Ward, S. A. Current drug development portfolio for antimalarial therapies. Curr. Opin. Pharmacol. 2005, 5, 473-478.
7. Biot, C. Ferroquine: a new weapon in the fight against malaria. Curr. Med. Chem.: Anti-infect. Agents, 2004, 3, 135-147.
8. Pink, Richard; Hudson, A.; Mouris, M.-A.; Bendig, M. Opportunities and Challenges in Antiparasitic Drug Discovery. Nature Rev. Drug Discovery 2005, 4, 727-740.
9. Pierrot, C.; Lafitte, S.; Dive, D.; Fraisse, L.; Brocard, J.; Khalife, J. Analysis of immune response patterns in naive and Plasmodium berghei-infected young rats following a ferroquine treatment. Int. J. Parasitol. 2005, 35, 1601-1610.
10. Biot, C.; Taramelli, D.; Forfar-Bares, I.; Maciejewski, L. A.; Boyce, M.; Nowogrocki, G.; Brocard, J. S.; Basilico, N.; Olliaro, P.; Egan, T. J. Insights into the Mechanism of Action of Ferroquine. Relationship between Physicochemical Properties and Antiplasmodial Activity Mol. Pharm. 2005, 2, 185-193.
11. Daher, W. E.; Pelinski, L.; Klieber, S.; Sadoun, F.; Meunier, V.; Bourrie, M.; Biot, C.; Guillou, F.; Fabre, G.; Brocard, J.; Fraisse, L.; Maffrand, J. P.; Khalife, J.; Dive, D. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab. Dispos. 2006, in press.
12. Warhurst, D. C., Steele, J. C., Adagu, I. S., Craig, J. C., Cullander, C. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J. Antimicrob. Chemother 2003, 52, 188-193.
13. Savarino, A.; Gennero, L.; Sperber, K.; Boelaert, J. R. The anti-HIV-1 activity of chloroquine. J. Clin. Virol. 2001, 20, 131-135.
14. Romanelli, F.; Smith, K. M.; Hoven, A. D. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr. Pharm. Des. 2004, 10, 2643-2648.
15. Savarino, A.; Lucia, M. B.; Rastrelli, E.; Rutella, S.; Golotta, C.; Morra, E.; Tamburrini, E.; Perno, C. F.; Boelaert, J. R.; Sperber, K.; Cauda, R. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J. Acquir. Immune Defic. Syndr. 2004, 35, 223-232.
16. Owen, A.; Janneh, O.; Hartkoorn, R. C.; Chandler, B.; Bray, P. G.; Martin, P.; Ward, S. A.; Hart, C. A.; Khoo, S. H.; Back, D. J. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J. Pharmacol. Exp. Ther. 2005, 314, 1202-1209.
17. Vincent, M. J.; Bergeron, E.; Benjannet, S.; Erickson, B. R.; Rollin, P. E.; Ksiazek, T. G.; Seidah, N. G.; Nichol, S. T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005, 2, 69.
18. Peiris, J. S. M.; Lai, S. T.; Poon, L. L. M.; Guan, Y.; Yam, L. Y. C.; Lim, W.; Nicholls, J.; Yee, W. K. S.; Yan, W. W.; Cheung, M. T.; Cheng, V. C. C.; Chan, K. H.; Tsang, D. N. C.; Yung, R. W. H.; Ng, T. K.; Yuen, K. Y. Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome Lancet 2003, 361, 1319-1325.
19. Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A.-E.; Humphrey, C. D.; Shieh, W.-J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J.-Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome N. Engl. J. Med. 2003, 348, 1953-1966.
20. Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H.-R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A. M.; Berger, A.; Burguiere, A.-M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J.-C.; Muller, S.; Rickerts, V.; Sturmer, M.; Vieth, S.; Klenk, H.-D.; Osterhaus, A. D. M. E.; Schmitz, H.; Doerr, H. W. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
21. He, J.-F.; Peng, G.-W.; Min, J.; Yu, D.-W.; Liang, W.-J.; Zhang, S.-Y.; Xu, R.-H.; Zheng, H.-Y.; Wu, X.-W.; Xu, J.; Wang, Z.-H.; Fang, L.; Zhang, X.; Li, H.; Yan, X.-G.; Lu, J.-H.; Hu, Z.-H.; Huang, J.-C.; Wan, Z.-Y.; Hou, J.-L.; Lin, J.-Y.; Song, H.-D.; Wang, S.-Y.; Zhou, X.-J.; Zhang, G.-W.; Gu, B.-W.; Zheng, H.-J.; Zhang, X.-L.; He, M.; Zheng, K.; Wang, B.-F.; Fu, G.; Wang, X.-N.; Chen, S.-J.; Chen, Z.; Hao, P.; Tang, H.; Ren, S.-X.; Zhong, Y.; Guo, Z.-M.; Liu, Q.; Miao, Y.-G.; Kong, X.-Y.; He, W.-Z.; Li, Y.-X.; Wu, C.-I.; Zhao, G.-P.; Chiu, R. W. K.; Chim, S. S. C.; Tong, Y.-k.; Chan, P. K. S.; Tam, J. S.; Lo, Y. M. D. Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China. Science 2004, 303, 1666-1669.
22. Guan, Y.; Zheng, B. J.; He, Y. Q.; Liu, X. L.; Zhuang, Z. X.; Cheung, C. L.; Luo, S. W.; Li, P. H.; Zhang, L. J.; Guan, Y. J.; Butt, K. M.; Wong, K. L.; Chan, K. W.; Lim, W.; Shortridge, K. F.; Yuen, K. Y.; Peiris, J. S.; Poon, L. L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003, 302, 276-278.
23. Shie, J. J.; Fang, J. M.; Kuo, C. J.; Kuo, T. H.; Liang, P. H.; Huang, H. J.; Yang, W. B.; Lin, C. H.; Chen, J. L.; Wu, Y. T.; Wong, C. H. Discovery of Potent Anilide Inhibitors against the Severe Acute Respiratory Syndrome 3CL Protease. J. Med. Chem. 2005, 48, 4469-4473.
24. Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., Cauda, R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect. Dis. 2003, 3, 722-727.
25. Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun 2004, 323, 264-268.
26. Aderounmu, A. F. In vitro assessment of the antimalarial activity of chloroquine and its major metabolites. Ann. Trop. Med. Parasitol. 1984, 78, 581-585.
27. Wei, Y.; Nygard, G. A.; Ellertson, S. L.; Khalil, S. K. Stereoselective disposition of hydroxychloroquine and its metabolite in rats. Chirality 1995, 7, 598-604.
28. Biot, C.; Delhaes, L.;, N'Diaye, C. M.; Maciejewski, L. A.; Camus, D.; Dive, D.; Brocard, J. S. Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds. Bioorg. Med. Chem. 1999, 7, 2843-2847.
29. For a review, see: De Clercq, E. Potential antivirals and antiviral strategies against SARS (severe acute respiratory syndrome)-coronavirus infections. Expert. Rev. Anti-Infective Ther. 2006, submitted for publication.
30. De Clercq, E., Descamps, J., Verhelst, G., Walker, R. T., Jones, A. S., Torrence, P. F., Shugar, D. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 1980, 141, 563-574.
31. De Clercq, E. Antiviral and antimetabolic activities of neplanocins. Antimicrob. Agents Chemother. 1985, 28, 84-89.
32. Pauwels, R., De Clercq, E., Desmyter, J., Balzarini, J., Goubau, P., Herdewijn, P., Vanderhaeghe, H., Vandeputte, M. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Methods 1987, 16, 171-185.
33. Durrand, V., Berry, A., Sem, R., Glaziou, P., Beaudou, J., Fandeur, T. Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol. Biochem. Parasitol. 2004, 136, 273-285.
34. Desjardins, R. E.; Canfield, J.; Haynes, D.; Chulay, D. J. Quantitative Assessment of Antimalarial Activity in Vitro by a Semi-automated Microdilution Technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.